Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
ObjectivesTo determine the contemporary effectiveness of exercise-based cardiac rehabilitation (CR) in terms of all-cause mortality, cardiovascular mortality and hospital admissions.Data sourcesStudies included in or meeting the entry criteria for the 2016 Cochrane review of exercise-based CR in patients with coronary artery disease.Study eligibility criteriaRandomised controlled trials (RCTs) of exercise-based CR versus a no-exercise control whose participants were recruited after the year 2000.Study appraisal and synthesis methodsTwo separate reviewers independently screened the characteristics of studies. One reviewer quality appraised any new studies and assessed their risk of bias using the Cochrane Collaboration’s recommended risk of bias tool. Data were reported as the risk difference (95% CI).ResultsWe included 22 studies with 4834 participants (mean age 59.5 years, 78.4% male). We found no differences in outcomes between exercise-based CR and a no-exercise control at their longest follow-up period for: all-cause mortality (19 studies; n=4194; risk difference 0.00, 95% CI −0.02 to 0.01, P=0.38) or cardiovascular mortality (9 studies; n=1182; risk difference −0.01, 95% CI −0.02 to 0.01, P=0.25). We found a small reduction in hospital admissions of borderline statistical significance (11 studies; n=1768; risk difference −0.05, 95% CI −0.10 to −0.00, P=0.05).Conclusions and implications of key findingsOur analysis indicates conclusively that the current approach to exercise-based CR has no effect on all-cause mortality or cardiovascular mortality, when compared with a no-exercise control. There may be a small reduction in hospital admissions following exercise-based CR that is unlikely to be clinically important.PROSPERO registration numberCRD42017073616.
ObjectivesTo determine the contemporary effectiveness of exercise-based cardiac rehabilitation (CR) in terms of all-cause mortality, cardiovascular mortality and hospital admissions.Data sourcesStudies included in or meeting the entry criteria for the 2016 Cochrane review of exercise-based CR in patients with coronary artery disease.Study eligibility criteriaRandomised controlled trials (RCTs) of exercise-based CR versus a no-exercise control whose participants were recruited after the year 2000.Study appraisal and synthesis methodsTwo separate reviewers independently screened the characteristics of studies. One reviewer quality appraised any new studies and assessed their risk of bias using the Cochrane Collaboration’s recommended risk of bias tool. Data were reported as the risk difference (95% CI).ResultsWe included 22 studies with 4834 participants (mean age 59.5 years, 78.4% male). We found no differences in outcomes between exercise-based CR and a no-exercise control at their longest follow-up period for: all-cause mortality (19 studies; n=4194; risk difference 0.00, 95% CI −0.02 to 0.01, P=0.38) or cardiovascular mortality (9 studies; n=1182; risk difference −0.01, 95% CI −0.02 to 0.01, P=0.25). We found a small reduction in hospital admissions of borderline statistical significance (11 studies; n=1768; risk difference −0.05, 95% CI −0.10 to −0.00, P=0.05).Conclusions and implications of key findingsOur analysis indicates conclusively that the current approach to exercise-based CR has no effect on all-cause mortality or cardiovascular mortality, when compared with a no-exercise control. There may be a small reduction in hospital admissions following exercise-based CR that is unlikely to be clinically important.PROSPERO registration numberCRD42017073616.
More than 6 million patients are on anticoagulant therapy and more than one third of adults take antiplatelet therapy in the United States, many of whom will require a surgical procedure while on treatment. The answers to questions regarding periprocedural thrombotic therapy are not at all straightforward and there is tremendous variability in practice across the country and across specialties. While there will always be nuances in clinical care that necessitate variation in practice patterns, algorithms for care allow for less ambiguity and they provide guidelines that are consistent with the most recent evidence in the literature. In this review, we provide: 1) a framework for periprocedureal antithrombotic therapy around the time of surgical procedures, 2) an approach for considering the risk of bleeding at the time of surgery as well as the risk of a thrombotic or thromboembolic event should the antithrombotic therapy be stopped, and 3) a strategy for managing periprocedural bridging therapy. KEY WORDSperiprocedural anticoagulation, antithrombotic therapy, thrombosis, bleeding risk, oral anticoagulation. n IS ANTITHROMBOTIC THERAPY REQUIRED?Answering a question regarding antithrombotic therapy should start with the consideration of whether or not the anticoagulation is still indicated in the first place. However, assuming the patient still has an indication for anticoagulation (and assuming a non-emergent surgery), the next question involves answering questions regarding surgical bleeding risk and the risk of thrombosis/thromboembolism if therapy is withheld. n BLEEDING RISKOne of the major risk-stratifications in assessing bleeding risk involves the risk inherent to the surgery or procedure. There is minimal data to guide decisions regarding procedural bleeding risk. The 2 main factors that impact bleeding risk are the type of procedure and the patient factors that interfere with hemostasis. A frequently cited reference with regard to surgical bleeding is from the American College of Chest Physicians, 1 which used expert consensus to generate a list of high-risk procedures. Interestingly, the major reference for surgical bleeding risk dates back to a metaanalysis of perioperative subcutaneous heparin use for the prevention of pulmonary embolism in 1988.2 Table 1 includes a list of high-risk procedures compiled from these consensus guidelines as well as another recent review. 1,3 In general, this list comprises surgeries that involve highly vascular organs or large incisions. An extensive list of surgical procedures and their associated risk has also been compiled as an appendix to a recent review on periprocedural antithrombotic therapy 4 (also based on expert opinion).There are several validated nonprocedural factors that increase bleeding risk and these include abnormal renal function, nonsteroidal anti-inflammatory medications, low platelet count, and liver disease/coagulopathy. These factors have been combined into a variety of bleeding risk scores: (1) and (4) ATRIA (anticoagulation and risk f...
Cardiovascular diseases are currently the most common causes of death worldwide, and most deaths from cardiovascular diseases are associated with coronary artery disease (CAD). CAD as a whole is a serious problem for the world’s population, and acute coronary syndrome (ACS) is associated with high morbidity, mortality and a great financial burden on the health care system. This is an urgent situation in which diagnostic and treatment measures must be performed as soon as possible from the moment of onset of the disease. Diagnosis of ACS begins with a thorough clinical assessment of the patient’s symptoms, electrocardiogram and blood troponin levels, as well as a history of the disease. Key components in the treatment of ACS include coronary revascularization when indicated and prompt initiation of adequate antiplatelet therapy. The presented literature review is devoted to the problems of adequate antiplatelet therapy in patients with ACS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.